RHYTHM PHARMACEUTICALS, INC.RYTMEarnings & Financial Report
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
Revenue
$57.3M
Gross Profit
$52.5M
Operating Profit
$-47.1M
Net Profit
$-47.5M
Gross Margin
91.6%
Operating Margin
-82.2%
Net Margin
-83.0%
YoY Growth
36.9%
EPS
$-0.73
RHYTHM PHARMACEUTICALS, INC. Q4 FY2025 Financial Summary
RHYTHM PHARMACEUTICALS, INC. reported revenue of $57.3M (up 36.9% YoY) for Q4 FY2025, with a net profit of $-47.5M (down 9.6% YoY) (-83.0% margin). Cost of goods sold was $4.8M, operating expenses totaled $99.5M.
Key Financial Metrics
| Total Revenue | $57.3M |
|---|---|
| Net Profit | $-47.5M |
| Gross Margin | 91.6% |
| Operating Margin | -82.2% |
| Report Period | Q4 FY2025 |
RHYTHM PHARMACEUTICALS, INC. Annual Revenue by Year
RHYTHM PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $189.8M).
| Year | Annual Revenue |
|---|---|
| 2025 | $189.8M |
| 2024 | $130.1M |
| 2023 | $77.4M |
RHYTHM PHARMACEUTICALS, INC. Quarterly Revenue & Net Profit History
RHYTHM PHARMACEUTICALS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $60.1M | +83.8% | $-55.6M | -92.6% |
| Q4 FY2025 | $57.3M | +36.9% | $-47.5M | -83.0% |
| Q3 FY2025 | $51.3M | +54.3% | $-52.9M | -103.1% |
| Q2 FY2025 | $48.5M | +66.8% | $-46.6M | -96.1% |
| Q1 FY2025 | $32.7M | +25.9% | $-49.5M | -151.4% |
| Q4 FY2024 | $41.8M | +72.6% | $-43.3M | -103.6% |
| Q3 FY2024 | $33.3M | +47.8% | $-43.6M | -131.2% |
| Q2 FY2024 | $29.1M | +51.3% | $-32.3M | -110.9% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.1M | $33.3M | $41.8M | $32.7M | $48.5M | $51.3M | $57.3M | $60.1M |
| YoY Growth | 51.3% | 47.8% | 72.6% | 25.9% | 66.8% | 54.3% | 36.9% | 83.8% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $381.8M | $363.6M | $392.3M | $386.7M | $372.7M | $506.9M | $480.2M | $442.3M |
| Liabilities | $202.4M | $210.9M | $227.7M | $223.6M | $239.2M | $211.2M | $210.2M | $204.7M |
| Equity | $39.3M | $11.2M | $21.7M | $18.9M | $-11.9M | $148.8M | $139.1M | $122.9M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-29.1M | $-25.2M | $-18.8M | $-40.4M | $-23.3M | $-26.6M | $-25.4M |